SCHEMBL6532032

SCHEMBL6532032

COC(=O)[C@H](CC(C)C)Nc1cc(Sc2ccc(OC)cc2)cc(Nc2cccc(F)c2)[n+]1[O-]

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C19 P33261 2/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP2C9 P11712 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CTSK P43235 6/20 0.39
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
CTSL P07711 2/20 0.35
CTSS P25774 2/20 0.35
HPGD P15428 1/20 0.35
CYP3A4 P08684 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6530218 0.89 CTSK (0.38) CYP1A2CYP2D6CYP2C19ALDH1A1CYP2C9
SCHEMBL6509993 0.85 CTSK (0.43) CYP1A2CYP2D6CYP2C19ALDH1A1CYP2C9
SCHEMBL6510002 0.85 CTSK (0.43) CYP1A2CYP2D6CYP2C19ALDH1A1CYP2C9
SCHEMBL6510461 0.83 ALDH1A1 (0.40) CYP1A2CYP2D6CYP2C19ALDH1A1CYP2C9
SCHEMBL6510466 0.83 ALDH1A1 (0.40) CYP1A2CYP2D6CYP2C19ALDH1A1CYP2C9
SCHEMBL6529389 0.82 KMT2A (0.40) MAPTMEN1KMT2A
SCHEMBL6531422 0.82 KMT2A (0.40) MAPTMEN1KMT2A
SCHEMBL6513215 0.80 CTSK (0.40) CYP1A2CYP2D6CYP2C19ALDH1A1CYP2C9
SCHEMBL6513221 0.80 CTSK (0.40) CYP1A2CYP2D6CYP2C19ALDH1A1CYP2C9
SCHEMBL6513761 0.80 ALDH1A1 (0.39) CYP1A2CYP2D6CYP2C19ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005003103-A2 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ASTRAZENECA AB (SE) 2005-01-13 WO claimed
WO-2005003103-A2 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ASTRAZENECA AB (SE) 2005-01-13 WO disclosed
WO-2005003103-A2 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ASTRAZENECA AB (SE) 2005-01-13 WO disclosed